Precigen opened lower at $4.70, compared with its previous close of $4.72. In the last trading session, the stock traded between $4.59 and $4.91. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Precigen is now worth
$ 106.54
Giving a profit of
$ 6.54 (6.54%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.08 (-1.59%)
Day High
$4.91
Day Low
$4.59
Day Open
$4.70
Prev Close
$4.72
Volume
39,45,757
1W Return
-8.13%
1M Return
-39.40%
3M Return
-32.21%
6M Return
10.60%
1Y Return
17.30%
Market Cap ($ Mn)
1,665
PE Ratio
-
PB Ratio
57.00
PEG Ratio
-
ROE
-2,483.92%
ROCE
-221.37%
EPS (TTM)
$0.10
1 Week
-8.13%
1 Month
-39.40%
3 Months
-32.21%
6 Months
10.60%
9 Months
-5.40%
Precigen Q3FY26 Results: Net income $35.8M, revenue up 37% QoQ
Net income reached $35.8 million with net product revenue up 37% QoQ to $72.9 million. Positive operating cash flow achieved ahead of schedule, with cash and investments rising to $51.0 million. Over 500 patients have initiated treatment, with coverage secured for more than 315 million U.S. lives. New five-year data supports sustained disease control, while competitor entry is delayed by at least 18 months. AdenoVerse platform received FDA Platform Technology Designation, potentially shortening future development timelines.
2 days agoB. Riley initiates coverage on Precigen with buy rating and $12 target
B. Riley Securities initiated coverage on Precigen (NASDAQ: PGEN). Analyst Yuan Zhi assigned a Buy rating to the stock. The firm announced a price target of $12.
1mo agoPrecigen Q2 Results: Profitability returns as PAPZIMEOS revenue doubles
Precigen turned profitable in Q2 as net product revenue from PAPZIMEOS doubled to $53.1 million. The FDA-approved therapy for RRP benefits from broad payer coverage and seven-year market exclusivity through August 2032. PRGN-2009, targeting HPV-driven cancers, showed a 20% to 30% objective response rate in Phase 1 combination therapy. Phase 2 trials are underway for oropharyngeal and cervical cancers, with head and neck data expected in Q4.
2mo agoHC Wainwright Reiterates Buy on Precigen, Holds $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates a Buy rating on Precigen (NASDAQ: PGEN). The firm maintains its $14 price target, indicating sustained confidence in the company's growth trajectory and valuation potential.
3mo agoPrecigen secures FDA orphan drug exclusivity for PAPZIMEOS through August 2032
Precigen Inc. has secured orphan drug exclusivity from the FDA for PAPZIMEOS, its treatment for recurrent respiratory papillomatosis (RRP), providing market protection through August 2032. Long-term data presented at the ASCO Annual Meeting indicates that 83% of complete responders remained surgery-free for at least 36 months. The drug is currently commercially available across the United States.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Precigen is now worth
$ 106.54
Giving a profit of
$ 6.54 (6.54%)
Note: Past profits do not guarantee future returns.
